Drug Profile
Colestyramine - Albireo
Alternative Names: A 3384Latest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Albireo AB
- Developer Albireo AB; Albireo Pharma
- Class Antidiarrhoeals; Antihyperlipidaemics
- Mechanism of Action Bile acid binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Primary bile acid malabsorption
- No development reported Intrahepatic cholestasis
Most Recent Events
- 02 Mar 2023 Albireo Pharma has been acquired by Ipsen
- 10 May 2019 ALBIREO PHARMA plans a clinical trial for Primary bile acid malabsorption in USA in 2020
- 23 Nov 2016 No recent reports on development identified - Phase-I for Intrahepatic cholestasis (Combination therapy, In volunteers) in United Kingdom (PO)